GEN Exclusives

More »

GEN News Highlights

More »
Sep 14, 2010

Life Technologies Inks Multiple Out-Licensing Deals for CHO Cell Lines

Life Technologies Inks Multiple Out-Licensing Deals for CHO Cell Lines

Firm also offered commercial use rights to a number of institutions already using the lines.

  • Life Technologies negotiated CHO cell-line license agreements with a number of companies, giving them rights to produce recombinant proteins used as therapeutic agents and vaccines. Detailed cell-line history documentation packages that are suitable for submission to the FDA as part of IND filings are provided to licensees, eliminating the need for expensive preliminary testing.

    New licensees include Advanced BioScience Laboratories, CNA Development, Chong Kun Dang Pharmaceutical, and DiNonA of Korea, U.K. firm RecipharmCobra Biologics, evitria SA in Switzerland, Fusion Antibodies of Northern Ireland, Indian Immunologicals, and others. Commercial-use rights have additionally been offered to many of the hundreds of institutions already using Life Technologies’ cell lines for R&D, the company reports.

    Life Technologies explains that its CHO lines are optimized for growth in suspension in the company’s chemically defined GIBCO® media, permitting protein manufacturers to obtain good yields while reducing serum-associated risks. They have also been shown to be free of standard pathogens, making them well suited for therapeutic manufacturing, the firm adds.

    “This new global licensing program is part of a larger strategy to monetize our rich intellectual property, technology, and product portfolio,” remarks Paul Grossman, Ph.D., svp of strategy and corporate development at Life Technologies. “The program is a stellar example of one of the creative ways in which the company plans to provide broader access to the company’s intellectual property including patents, biological materials, trademarks, and trade secrets, which are designed to lead to revolutionary developments in drug and vaccine manufacture to ultimately improve healthcare.”

    Life Technologies possesses an intellectual property estate of approximately 3,900 patents and exclusive licenses. It obtained revenues of $3.3 billion in 2009, an increase of 5% over the $3.14 billion reported for 2008, as if Invitrogen and Applied Biosystems had been combined.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?